GleamWall
中文EN

MCRB Seres Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1609809 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY505.4%
TTM net income YoY-970.5%
TTM EPS YoY-1,766.7%
Revenue 3-yr CAGR-74.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,656.9%
Net margin-2,209.6%
FCF margin-3,010.4%
EBITDA margin-3,521.1%

Returns

ROE-144.3%
ROA-44.9%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio16.2%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$789,000$0
R&D expense$49.06M$64.60M
SG&A expense$39.16M$53.18M
Operating income-$93.97M-$121.31M
Interest expense$0$0
Income tax$0$0
Net income$5.70M$136,000
EBITDA-$89.84M-$115.85M
EPS (basic)0.640.00
EPS (diluted)0.640.00
Weighted avg. shares (diluted)8.87M7.77M
Balance sheet
Cash & equivalents$45.77M$39.46M
Receivables$157,000$0
Current assets$49.38M$38.67M
PP&E, net$7.63M$11.53M
Total assets$138.19M$139.81M
Current liabilities$19.32M$41.22M
Total liabilities$93.97M$126.03M
Shareholders' equity$44.22M$13.78M
Shares outstanding9.56M8.65M
Cash flow statement
Operating cash flow$1.12M-$148.61M
Capital expenditure$252,000$380,000
Free cash flow$865,000-$148.99M
Investing cash flow-$42,000$142.29M
Financing cash flow$13.90M-$90.37M
Depreciation & amortization$4.13M$5.47M
Stock-based compensation$10.84M$20.97M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.